Chosen from thousands of entries worldwide, GALY secured a place among the Top 3 finalists in the Water, Food & Agriculture category at the Edison Awards. The company earned the Silver award for its Biocrafted Cocoa & Cotton platform, an innovative system that cultivates natural materials in controlled tank environments rather than relying on conventional field farming.

A Landmark Moment on the International Stage
At the Edison Awards gala, GALY’s chocolate was showcased in a live tasting event alongside NextCoa, a cocoa-free chocolate alternative created by Cargill and Voyage Foods. Both innovations address the future of chocolate production from different angles: NextCoa replicates chocolate flavors using alternative plant ingredients, while GALY cultivates chocolate directly from cacao cells grown in tanks.

During the tasting, a participant described GALY’s chocolate as “Divine,” highlighting not only its flavor profile but also the disruptive promise of its production technology.

GALY also gained visibility through major international media outlets, including CNN and Access Hollywood, further cementing its status as one of the standout innovators of the 2026 awards season.

Expanding Beyond Cocoa
Although the company’s cocoa breakthrough has attracted widespread attention, GALY’s ambitions extend far beyond chocolate. Its broader biocrafting platform is designed to support the production of multiple commodities, beginning with cocoa and cotton, with additional applications planned for the future.

The GALY Platform
Rather than cultivating crops in agricultural fields, GALY produces materials inside tanks, allowing manufacturing to continue without dependence on climate conditions or land availability. The method is intended to deliver stable, scalable production while improving supply chain reliability, consistency, and transparency across industries such as cocoa and cotton.

Moving Toward Commercial Production
Following this recognition, GALY is preparing for the next stage of its expansion. The company aims to open its first commercial-scale production facility this year, transitioning from pilot-stage innovation to full industrial manufacturing. Its chocolate products are being developed in partnership with leading Swiss collaborators, combining advanced food technology with renowned chocolate-making expertise.

Leadership Perspectives
“This recognition goes beyond a single product — it demonstrates that we can fundamentally transform the way essential and beloved products are made around the world,” said Luciano Bueno.

“The most impactful innovations are those capable of reshaping entire industries, and GALY’s platform carries that level of transformative potential,” said Carmichael Roberts, an Edison Achievement Award honoree.

Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial (NCT05790694/CTR20221961) of HBM9378 (also referred to as SKB378 or WIN378).

The study, led by Dr. Min Xu, a respiratory medicine specialist at Chengdu Fifth People’s Hospital, appears in the peer-reviewed journal Drug Design, Development and Therapy. Findings from the trial highlight a strong safety profile and a prolonged half-life, supporting continued investigation of HBM9378 in patients with serious immune-related conditions.

HBM9378 is a fully human monoclonal antibody with an extended half-life that targets thymic stromal lymphopoietin (TSLP). It is being co-developed by Harbour BioMed and Kelun-Biotech. The randomized, double-blind, placebo-controlled, single-ascending-dose (SAD) study enrolled 50 healthy adults to assess safety, tolerability, pharmacokinetics (PK), and immunogenicity. Participants were divided into five dose groups—20 mg, 60 mg, 200 mg, 600 mg, and 900 mg—with each cohort consisting of ten individuals, eight receiving HBM9378 and two receiving a placebo.

Results showed that treatment-emergent adverse events (TEAEs) occurred at similar rates across both the treatment and placebo groups, with no evidence of increased safety concerns at higher doses. The median time to reach peak concentration (Tmax) ranged between 4.05 and 14.1 days, while the average half-life (T1/2) was between 55.0 and 65.8 days. Drug exposure, measured by Cmax and AUC, rose proportionally with increasing doses from 20 mg to 900 mg. Anti-drug antibodies (ADA) were detected in 5% of participants (2 out of 40), with no observed clinical effects or impact on drug exposure. Notably, no injection site reactions were reported in any group.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, described the Phase I results as an important step forward in developing new treatments for immune-related diseases. He emphasized that the favorable safety profile and extended half-life strengthen confidence in the drug’s potential to address unmet needs in conditions such as severe asthma and chronic obstructive pulmonary disease (COPD).

Dr. Min Xu, Principal Investigator of the study, noted that HBM9378 was well-tolerated and demonstrated a promising pharmacokinetic profile in healthy volunteers. He added that its long half-life could allow for less frequent dosing, which may improve patient adherence and overall treatment outcomes. The findings pave the way for further clinical trials to evaluate the drug’s effectiveness in individuals with severe immunological disorders.